Drug-Induced Lung Injury, Radiation-Induced Lung Injury
Conditions
Interventions
atients were divided into those with and without lung injury (DLI, drug-induced lung injury
RILI, radiation-induced lung injury) during follow-up for between-group comparison.:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.The age range is 18–75 years, with an ECOG PS score of 0–2. 2.Intended to initiate treatment with a high risk of lung injury, including: (1) High-risk medications (specific immune checkpoint inhibitors, molecular targeted drugs, chemotherapeutic agents, antibiotics, or cardiovascular drugs, etc.); (2) Thoracic radiotherapy (with radiation target volumes involving lung tissue). 3.Expected survival =6 months, with complete baseline clinical assessment data (including HRCT imaging, pulmonary function tests, and laboratory examinations, etc.); 4.The functions of the major organs are generally normal, meeting the routine indications for treatment. 5.Sign the informed consent form for participation in this clinical trial.
Exclusion criteria
Exclusion criteria: 1.Previously diagnosed with severe interstitial lung disease, pulmonary fibrosis, or currently in the active phase of a severe pulmonary infection. 2.Patients who have had a severe active pulmonary infection within the 4 weeks prior to enrollment and whose imaging findings have not yet fully resolved. 3.Patients who have previously received thoracic radiotherapy. 4.Patients with severe coagulation disorders or other conditions that make it unsuitable or who refuse to undergo the collection of biological specimens such as blood and sputum. 5.Patients who have severe claustrophobia or physical limitations (e.g., inability to lie flat) that objectively prevent them from cooperating in completing a high-resolution computed tomography (HRCT) examination. 6.Patients with other malignant tumors that are not effectively controlled, apart from the primary disease. 7.Female patients who are pregnant or breastfeeding. 8.According to the investigator’s judgment, there are concomitant diseases that seriously endanger the safety of the subject, may confound the study results, or affect the subject’s ability to complete this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the (ROC) curve, Sensitivity, Specificity;Calibration;Decision Curve Analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptoms;Imaging parameters;Pulmonary function parameters; | — |
Countries
China
Contacts
Public ContactBingwen Zou
West China Hospital of Sichuan University
Outcome results
None listed